Denver, Colorado, (PRWEB) November 07, 2014
CannLabs, Inc.(OTCQB: CANL), the leading provider of proprietary cloud based analytics, and scientific testing methodologies relating to cannabis, today announced both state and local approval for an independent testing facility in Nevada to analyze medical cannabis. The license has been granted to CannLabs Nevada, Inc. (CannLabs NV).
The laboratory will be based in North Las Vegas, which is in the heart of Nevadas Cannabis Greenbelt. The state-of-the-art laboratory will have capabilities to provide all state-mandated tests including potency profiles, microbiological contaminates, heavy metal analysis and pesticide and residual solvent screenings. Additionally, CannLabs-NV, utilizing over 4 years of proprietary analytics will offer a broad spectrum of consultative services; formulation consultation, analytics evaluation and operational consultation, including offering assistance to operators with the remediation of contaminated grows and identifying manufacturing issues.
With the granting of the license to CannLabs NV, CannLabs Inc. enters one of the largest and most rapidly growing medical marijuana markets in the country. CannLabs-NV is the health and safety checkpoint in the seed-to-sale pipeline, assuring the well being of the patients of Nevada, said Mark Mirken, Chief Executive Officer of CannLabs. Early projections indicate that the matured market for medical cannabis testing in Nevada could exceed $ 15 million. We estimate the lab will capture upwards of 30% of the market by the end of the first year of full market maturity, added Mirken.
“As Nevada moves forward with the cultivation and sale of medical marijuana, our top priority is protecting the health and safety of consumers. Thats why Im pleased to welcome CannLabs expertise and professionalism to Southern Nevada. Having visited their Denver facility, I am confident the opening of their laboratory here will bring the highest standards of quality and safety to our state’s developing medical cannabis industry,” said Rep. Dina Titus (NV-01).
Under an agreement with Carbon Bonds Holdings, a wholly owned subsidiary of CannLabs, Inc., the company provides administrative services and licenses proprietary software to CannLabs Nevada, Inc. CannLabs-NV is planning to begin construction in early 2015; the project will take approximately 6 months to complete and cost in excess of $ 1 million. When completed, the 8,000 sq. ft. facility will be in close proximity to an estimated 1.5 million sq.ft. of projected cannabis production. Located at the highly visible corner of N. Las Vegas Blvd and Cheyenne Ave, with convenient access to Interstate 15, the projects completion is timed to match the testing demand generated from Nevadas first large scale cannabis crops.
The testing laboratory is licensed by the city of North Las Vegas and the Nevada Division of Public and Behavioral Health. Nevada has some of the most stringent quality control standards in the nation and adheres to the American Herbal Pharmacopoeia